Working with clinical and research colleagues from Leeds and Bradford, we are in the process of developing a strategy to develop a clinical and academic dermato-rheumatology grouping in Leeds/Bradford based around a unique clinical service working across the cities. This incorporates a wide range of researchers working together in inflammatory disease, including immunology, allergy and genetics. We are also involved in the ALPHA trial.
Contact Dr Miriam Wittmann for more information email@example.com
Psoriatic arthritis was ‘discovered’ in Leeds in the 1960s and 1970s through the pioneering work of Verna Wright and John Moll. Recent advances in this field have also come from Leeds; the entheseal hypothesis, the CASPAR criteria, and now the first treatment strategy trial (tight control of inflammation in early psoriatic arthritis (TICOPA)). The psoriatic arthritis group (Philip Helliwell, Robin Waxman, Laura Coates, Laura Savage, Miriam Wittmann, Helena Marzo-Ortega, Dennis McGonagle) aims to build on this reputation by further developing the following areas: new strategy trials, outcome measures, phenotyping, genetics and biomarkers.
Contact Dr Philip Helliwell for more information firstname.lastname@example.org